Pfizer completes its acquisition of Metsera

Pfizer said on Nov. 13, 2025, that it has completed its acquisition of Metsera, a clinical-stage biotech developing obesity and cardiometabolic drugs. Pfizer bought all outstanding Metsera shares for $65.60 each in cash, which it valued at an enterprise value of about $7.0 billion, plus a contingent value right (CVR) worth up to $20.65 per share tied to three specified clinical and regulatory milestones ^[1]. Metsera is now a wholly owned subsidiary of Pfizer, and its stock stopped trading on the NASDAQ Global Select Market after the market close that day ^[1].

The deal ends a public bidding war. Metsera first agreed to be acquired by Pfizer in late September, but Novo Nordisk — the maker of Wegovy (semaglutide) — later made a surprise counteroffer of $6.5 billion upfront, topping Pfizer's $4.9 billion upfront bid ^[2]. Pfizer sued and argued that Novo's move was "an attempt by a company with a dominant market position to suppress competition in violation of the law by taking over an emerging American challenger" ^[2]. A Delaware judge blocked Pfizer's effort to halt Novo's bid, while the Federal Trade Commission warned Novo that the structure of its proposed purchase might not comply with U.S. merger law ^[2]. Metsera accepted Pfizer's raised offer late on Nov. 7 ^[2]. Counting the CVR, the total deal value is around $10 billion, up from the $7.3 billion value of the original September agreement ^[2].

What Pfizer bought

The centerpiece is MET-097i, an injectable GLP-1 receptor agonist that Pfizer describes as both weekly and monthly and "about to begin Phase 3 development" ^[1][2]. Pfizer also gains MET-233i, a monthly amylin analog being tested in Phase 1 both by itself and combined with MET-097i; an oral GLP-1 candidate in Phase 1; and additional preclinical "nutrient-stimulated hormone" therapeutics ^[1].

Amylin is a different hormone pathway than GLP-1, and several companies are testing amylin drugs alone and alongside GLP-1 medicines. None of the Metsera candidates is approved anywhere, and the sources do not give efficacy or safety data, trial start dates, or any expected filing or launch timeline ^[1][2].

Pfizer acknowledged the financial cost: the transaction is expected to be dilutive to earnings through 2030, largely so the company can invest more in late-stage pipeline candidates ^[1]. Fierce Biotech framed the same point as a multiyear drag on earnings while Pfizer funds development of Metsera's drugs ^[2]. Pfizer said an updated financial outlook will come with its 2026 guidance, expected later this year ^[1].

"By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it," Pfizer Chairman and CEO Albert Bourla said in the release ^[1][2].

Why it matters for patients

Nothing about this deal changes what is on pharmacy shelves today. Metsera's candidates are in Phase 1 or entering Phase 3, and drugs at that stage typically need years of testing before regulators decide whether to approve them ^[1]. The sources give no timeline for when — or whether — any of them could reach patients.

The longer-term significance is about competition and options. The obesity drug market is currently dominated by Novo Nordisk and Eli Lilly, with Novo already established through Wegovy (semaglutide) ^[2]. Pfizer, one of the largest U.S. drugmakers, is now buying its way into that field with a portfolio that includes a monthly injectable GLP-1 candidate and a monthly amylin candidate ^[1]. If those work and are approved, less frequent dosing would be a meaningfully different option than weekly injections — but that is a hypothesis being tested, not a result.

The fight over Metsera also shows how contested this space has become. Pfizer's antitrust argument and the FTC's warning letter to Novo both centered on whether an established leader should be allowed to absorb an emerging rival ^[2]. More competitors developing obesity drugs can, over time, affect pricing and supply, though the sources make no claims about future prices or access.

What happens next

• Pfizer says MET-097i is about to begin Phase 3 development; no start date was disclosed ^[1][2].
• Pfizer plans to provide an updated financial outlook including the acquisition's impact alongside its 2026 guidance, expected later in 2025 ^[1].
• The three specific milestones that trigger the CVR payments were not disclosed. Fierce Biotech noted Pfizer did not provide specifics on the exact goals ^[2].